US Bancorp DE Sells 8,442 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

US Bancorp DE trimmed its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 81.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,967 shares of the company’s stock after selling 8,442 shares during the period. US Bancorp DE’s holdings in Pacira BioSciences were worth $30,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in shares of Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after purchasing an additional 932 shares during the period. Park Place Capital Corp bought a new position in shares of Pacira BioSciences during the second quarter valued at about $46,000. Innealta Capital LLC purchased a new stake in shares of Pacira BioSciences during the second quarter worth about $50,000. nVerses Capital LLC grew its stake in shares of Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after purchasing an additional 1,600 shares during the last quarter. Finally, Natixis purchased a new position in Pacira BioSciences during the 1st quarter valued at about $95,000. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX opened at $16.64 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm has a market cap of $768.32 million, a price-to-earnings ratio of -8.18 and a beta of 0.82. The business has a 50-day simple moving average of $15.81 and a two-hundred day simple moving average of $20.60. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $35.95.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on PCRX. Raymond James lowered Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research report on Monday, August 12th. Barclays decreased their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Truist Financial cut Pacira BioSciences from a “buy” rating to a “sell” rating and cut their price objective for the company from $30.00 to $8.00 in a research report on Tuesday, August 13th. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Pacira BioSciences in a research note on Friday, November 8th. Finally, Piper Sandler cut Pacira BioSciences from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $42.00 to $11.00 in a research note on Monday, August 12th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $23.50.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.